Edgewise Therapeutics Announces Positive 12-Month Topline Results From The ARCH Open Label Study Of EDG-5506 In Adults With Becker Muscular Dystrophy (BMD) – Sustained positive trend in North Star Ambulatory Assessment (NSAA) scores relative to BMD natural history – –...
Vega Therapeutics Receives FDA Orphan Drug Designation for VGA039 for the Treatment of von Willebrand Disease SOUTH SAN FRANCISCO, CA, May 23, 2023 – Vega Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies for rare blood disorders,...
HARPOON THERAPEUTICS ANNOUNCES COMPLETION OF PLANNED PATIENT ENROLLMENT IN PHASE 1 STUDY OF HPN217 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA SOUTH SAN FRANCISCO, Calif., June 27, 2023 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage...
Silver Cross Hospital Expands Use of Kyruus’ Award-Winning Online Scheduling Solution Across Specialties and Services 348-Bed Community Hospital Builds on Success of Preventive and Diagnostic Care Scheduling Impact Boston, MA – June 20, 2023 – Kyruus, the leader in...
Thoma Bravo Announces Strategic Growth Investment in Bluesight to Support the Company’s Acquisition of MedacistCombination Creates Leading Hospital Pharmacy Software Platform ALEXANDRIA, Va. and CHESHIRE, Conn. and SAN FRANCISCO, Calif.—Thoma Bravo, a leading...
Recent Comments